158 research outputs found

    LĂ©iomyosarcome pleural primitif: Ă  propos d’un cas

    Get PDF
    Nous rapportons le cas d'un lĂ©iomyosarcome pleural primitif, localement avancĂ©, chez un homme de 64 ans, traitĂ© par chimiothĂ©rapie. La circonstance de dĂ©couverte est une masse intra-thoracique, augmentant progressivement de volume, dans un contexte de fiĂšvre et d'altĂ©ration de l'Ă©tat gĂ©nĂ©ral. La tomodensitomĂ©trie abdominale a objectivĂ© la tumeur. L'exploration chirurgicale a rĂ©vĂ©lĂ© une tumeur pleurale, trĂšs localement avancĂ©e, envahissant le mĂ©diastin. Une simple biopsie a Ă©tĂ© rĂ©alisĂ©e. L'examen anatomopathologique avec complĂ©ment immunohistochimique Ă©tait en faveur d'un lĂ©iomyosarcome de haut grade. Notre patient a reçu une chimiothĂ©rapie Ă  base de Doxorubicine Ă  la dose de 60 mg / mÂČ, administrĂ©e tous les 21 jours. L'Ă©valuation aprĂšs 6 cycles de chimiothĂ©rapie a retrouvĂ© un bĂ©nĂ©fice clinique et une rĂ©ponse partielle radiologique estimĂ©e Ă  30%. Actuellement, il est en bon contrĂŽle.Key words: LĂ©iomyosarcome, plĂšvre, chimiothĂ©rapi

    CuriethĂ©rapie dans le traitement palliatif du cancer de l’oesophage

    Get PDF
    Les patients atteints du cancer de l'oesophage ont souvent une maladie localement avancĂ©e, la dysphagie est le symptĂŽme majeur chez la plupart de ces patients, plusieurs modalitĂ©s thĂ©rapeutiques ont Ă©tĂ© utilisĂ©es pour amĂ©liorer cette dysphagie. Le but de ce travail est d'Ă©tudier l'efficacitĂ© et la tolĂ©rance de la curiethĂ©rapie haut dĂ©bit de dose (HDR) endo-luminale dans le traitement palliatif des cancers de l'oesophage inopĂ©rable. Sur une pĂ©riode de 15 ans, l'Ă©tude a inclus les patients atteints de cancer de l'oesophage inopĂ©rable et/ou mĂ©tastatique avec une dysphagie, sans extension Ă  l'hypopharynx ou a la trachĂ©e et qui ont bĂ©nĂ©ficiĂ© d'une curiethĂ©rapie HDR avec ou sans radiothĂ©rapie externe Ă  visĂ©e palliative. Au total 46 patients ont Ă©tĂ© inclus dans l'Ă©tude, 58,7% Ă©taient des hommes,  42,2% avaient une dysphagie grade 2 et 37,8 % Ă©taient aphagiques, 78,6 % des patients Ă©taient performance satus PS 2, l'amaigrissement Ă  Ă©tĂ© trouvĂ© chez 81,4%, la localisation de la tumeur Ă©tait surtout au niveau du tiers moyen et infĂ©rieur dans 97,8%, la hauteur mĂ©diane de la tumeur Ă©tait de 7 cm (5,5-9), le carcinome Ă©pidermoĂŻde Ă©tait le type histologique le plus frĂ©quent chez 31 patients (70,5%). AprĂšs un mĂ©diane de suivi de 5 mois, l'amĂ©lioration de la dysphagie a Ă©tĂ© retrouvĂ©e chez 76% des  malades (p1]. LÂŽincidence la plus Ă©levĂ©e est observĂ©e dans certains pays notamment en Asie et en Afrique, et lÂŽincidence dans les pays dĂ©veloppĂ©s occidentaux est en augmentation [2]. Selon le registre du cancer de Rabat 2006-2008, le cancer de l'oesophage est rare et constitue 1,5% de tous les cancers chez l'homme [3]. Le taux de survie globale Ă  5 ans est de 8%, avec 80% des dĂ©cĂšs liĂ©s Ă  l'Ă©volution locale de la maladie [4]. Pour la minoritĂ© des patients avec une maladie localisĂ©e, le traitement par  radiochimiothĂ©rapieconcomitante avec ou sans chirurgie permet une amĂ©lioration de la survie [5]. Plus de 50% des patients atteints de cancer de lÂŽoesophage ont une maladie inopĂ©rable au moment du diagnostic due Ă  une tumeur localement avancĂ©e, des mĂ©tastases ou un mauvais Ă©tat gĂ©nĂ©ral avec une  mĂ©diane de survie globale de 2,5 Ă  9,9 mois [6]. La majoritĂ© de ces patients ont besoin de soins palliatifs pour soulager la dysphagie qui est prĂ©sente chez plus de 70 % des patients et qui est responsable d'une dĂ©gradation importante de la qualitĂ© de vie [7]. À lÂŽheure actuelle,  plusieurs modalitĂ©s de prise en charge sont disponibles pour le traitement palliatif de cette dysphagie. Les options de traitement les plus  couramment utilisĂ©es comprennent le placement de stent mĂ©tallique   [8-10], le traitement au laser [11], et la curiethĂ©rapie avec ou sans radiothĂ©rapie externe et ou Ă©ventuellement une   chimiothĂ©rapie [12-15]. Une mĂ©ta-analyse a conclu qu'il n'y a pas de supĂ©rioritĂ© claire de l'une desmĂ©thodes utilisĂ©es dans la palliation du cancer de l'oesophage, le choix de l'une de ces mĂ©thodes dĂ©pend de l'expĂ©rience du centre et de l'Ă©tat du patient. Cette mĂ©taanalyse a aussi dĂ©montrĂ© que la pose d'une prothĂšse mĂ©tallique expansible et la curiethĂ©rapie Ă©taient les deux mĂ©thodes de rĂ©fĂ©rence, la premiĂšre Ă©tant la plus rapide pour amĂ©liorer la dysphagie, mais la seconde constitue une rĂ©elle alternative pouvant amĂ©liorer la survie et la qualitĂ© de vie [16]. Un inconvĂ©nient du traitement au laser est la nĂ©cessitĂ© de rĂ©pĂ©ter les sĂ©ances afin d'obtenir et de maintenir le bĂ©nĂ©fice [17, 18]. Dans notre centre la curiethĂ©rapie est souvent utilisĂ©e pour pallier Ă  la dysphagie. Le but de notre travail est de dĂ©terminer l'efficacitĂ© et la tolĂ©rance de la curiethĂ©rapie dans le traitement palliatif du cancer de l'oesophage

    Analysis and Design of a Cylindrical EBG-Based Directive Antenna

    Full text link

    Primary osteosarcoma of the breast: case report

    Get PDF
    Mammary sarcomas are very uncommon and make up less than 1% of all primary breast malignancies

    A critical review of mathematical models and data used in diabetology

    Get PDF
    The literature dealing with mathematical modelling for diabetes is abundant. During the last decades, a variety of models have been devoted to different aspects of diabetes, including glucose and insulin dynamics, management and complications prevention, cost and cost-effectiveness of strategies and epidemiology of diabetes in general. Several reviews are published regularly on mathematical models used for specific aspects of diabetes. In the present paper we propose a global overview of mathematical models dealing with many aspects of diabetes and using various tools. The review includes, side by side, models which are simple and/or comprehensive; deterministic and/or stochastic; continuous and/or discrete; using ordinary differential equations, partial differential equations, optimal control theory, integral equations, matrix analysis and computer algorithms

    Current Opinion and Practice on Peritoneal Carcinomatosis Management: The North African Perspective.

    Get PDF
    The status of peritoneal surface malignancy (PSM) management in North Africa is undetermined. The aim of this study was to assess and compare current practice and knowledge regarding PSM and examine satisfaction with available treatment options and need for alternative therapies in North Africa. This is a qualitative study involving specialists participating in PSM management in North Africa. The survey analyzed demographic characteristics and current knowledge and opinions regarding PSM management in different institutions. We also looked at goals and priorities, satisfaction with treatment modalities and heated intraperitoneal chemotherapy (HIPEC) usefulness according to specialty, country, years of experience, and activity sector. One-hundred and three participants responded to the survey (response rate of 57%), including oncologists and surgeons. 59.2% of respondents had more than 10 years experience and 45.6% treated 20-50 PSM cases annually. Participants satisfaction with PSM treatment modalities was mild for gastric cancer (3/10 [IQR 2-3]) and moderate for colorectal (5/10 [IQR 3-5]), ovarian (5/10 [IQR 3-5]), and pseudomyxoma peritonei (5/10 [IQR 3-5]) type of malignancies. Good quality of life and symptom relief were rated as main priorities for treatment and the need for new treatment modalities was rated 9/10 [IQR 8-9]. The perceived usefulness of systemic chemotherapy in first intention was described as high by 42.7 and 39.8% of respondents for PSM of colorectal and gastric origins, while HIPEC was described as highly useful for ovarian (49.5%) and PMP (73.8) malignancies. The management of PSM in the North African region has distinct differences in knowledge, treatments availability and priorities. Disparities are also noted according to specialty, country, years of expertise, and activity sector. The creation of referral structures and PSM networks could be a step forward to standardized PSM management in the region

    Common Variants in CDKAL1, CDKN2A/B, IGF2BP2, SLC30A8, and HHEX/IDE Genes Are Associated With Type 2 Diabetes and Impaired Fasting Glucose in a Chinese Han Population

    Get PDF
    OBJECTIVE— Genome-wide association studies have identified common variants in CDKAL1, CDKN2A/B, IGF2BP2, SLC30A8, HHEX/IDE, EXT2, and LOC387761 loci that significantly increase the risk of type 2 diabetes. We aimed to replicate these observations in a population-based cohort of Chinese Hans and examine the associations of these variants with type 2 diabetes and diabetes-related phenotypes

    Triple malignancy in a single patient including a cervical carcinoma, a basal cell carcinoma of the skin and a neuroendocrine carcinoma from an unknown primary site: A case report and review of the literature

    Get PDF
    <p>Abstract</p> <p>Introduction</p> <p>The occurrence of multiple primary cancers is rare. Only a few cases and patient reviews of an association of triple malignancy have been reported.</p> <p>Case presentation</p> <p>We report here a case of a 78-year-old Moroccan woman presenting initially with a synchronous double malignancy, the first in her cervix and the second in her skin. Our patient was treated with radiation therapy for both tumors and remained in good control for 17 years, when she developed a metastatic disease from a neuroendocrine carcinoma of an unknown primary site.</p> <p>Conclusions</p> <p>Although the association of multiple primary cancers can be considered a rare occurrence, improving survival in cancer patients has made this situation more frequent.</p
    • 

    corecore